Key Events This Week
13 Jul: Technical momentum shifts to sideways trend amid mixed signals
14 Jul: Technical momentum turns mildly bearish as stock declines 1.16%
16 Jul: Upgrade to Hold rating by MarketsMOJO; stock surges 3.54%
17 Jul: Stock retreats 1.90% to close the week at Rs.825.35
Monday, 13 July 2026: Technical Momentum Shifts to Sideways Amid Mixed Signals
Alembic Pharmaceuticals opened the week with a close at Rs.830.65, down 0.81% from the prior close of Rs.837.40. The stock’s technical momentum shifted from mildly bearish to a sideways trend, reflecting a complex interplay of bullish and bearish indicators. Weekly MACD and KST oscillators showed mild bullishness, while monthly indicators remained bearish, signalling a transitional phase. The stock traded within a range of Rs.816.60 to Rs.839.00, well below its 52-week high of Rs.1,064.70 but comfortably above the 52-week low of Rs.635.30. Despite the technical downgrade to a Sell grade earlier in July, the stock outperformed the Sensex’s marginal 0.01% gain on the day.
Tuesday, 14 July 2026: Momentum Turns Mildly Bearish as Price Declines Further
The stock declined further to close at Rs.821.00, down 1.16% on the day, as technical momentum shifted from sideways to mildly bearish. Daily moving averages indicated downward pressure, while weekly MACD remained bullish but monthly MACD turned bearish, underscoring the mixed outlook. The Relative Strength Index (RSI) remained neutral, suggesting consolidation. The Sensex fell 0.67% to 36,265.57, meaning Alembic outperformed the benchmark despite the decline. The stock’s intraday range of Rs.825.25 to Rs.844.95 reflected moderate volatility amid cautious investor sentiment.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Wednesday, 15 July 2026: Sharp Rebound on Upgrade to Hold Rating
Alembic Pharmaceuticals surged 3.54% to close at Rs.850.10, marking the week’s high. This rally coincided with MarketsMOJO’s upgrade of the stock’s rating from Sell to Hold, reflecting improved technical momentum and valuation metrics despite flat recent financials. The upgrade was supported by bullish weekly MACD and KST indicators, alongside positive On-Balance Volume (OBV) trends signalling accumulation. The stock’s enterprise value to capital employed ratio of 2.6 and PEG ratio of 0.8 highlighted attractive valuation relative to peers. Despite the positive momentum, the stock remained below its 52-week high, indicating room for further upside if momentum sustains. The Sensex also rebounded, gaining 0.31% to 36,378.34, but Alembic outperformed significantly.
Thursday, 16 July 2026: Mixed Technical Signals Amid Volatile Trading
The stock retreated slightly to Rs.841.35, down 1.03%, as technical momentum showed a sideways trend with mixed signals. Weekly indicators remained bullish, but monthly MACD and Bollinger Bands suggested caution. The daily moving averages stayed mildly bearish, tempering immediate upside potential. Intraday volatility was high, with prices fluctuating between Rs.818.95 and Rs.853.70. The upgrade to Hold rating and positive volume trends provided some support, but the stock faced resistance near Rs.854. The Sensex declined 0.13% to 36,331.82, with Alembic’s performance broadly in line with the market.
Alembic Pharmaceuticals Ltd. or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Friday, 17 July 2026: Week Ends with Decline Amid Profit Taking
The week concluded with Alembic Pharmaceuticals closing at Rs.825.35, down 1.90% on the day and 1.44% for the week. The decline followed profit-taking after midweek gains, with the stock retreating from its recent highs. Despite the drop, Alembic outperformed the Sensex, which was essentially flat with a negligible 0.00% weekly change. Technical indicators remain mixed, with weekly momentum positive but monthly signals cautious. Volume declined to 6,502 shares, reflecting subdued trading interest. Key support levels near Rs.818 and resistance around Rs.854 will be critical in determining the stock’s near-term direction.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-13 | Rs.830.65 | -0.81% | 36,508.75 | +0.01% |
| 2026-07-14 | Rs.821.00 | -1.16% | 36,265.57 | -0.67% |
| 2026-07-15 | Rs.850.10 | +3.54% | 36,378.34 | +0.31% |
| 2026-07-16 | Rs.841.35 | -1.03% | 36,331.82 | -0.13% |
| 2026-07-17 | Rs.825.35 | -1.90% | 36,505.40 | +0.48% |
Key Takeaways
Positive Signals: The upgrade to a Hold rating by MarketsMOJO on 15 July 2026 marked a significant technical improvement, supported by bullish weekly MACD, KST, and OBV indicators. Valuation metrics such as a low enterprise value to capital employed ratio (2.6) and PEG ratio (0.8) suggest the stock is attractively priced relative to earnings growth potential. Institutional holdings at 20.41% indicate confidence from sophisticated investors.
Cautionary Signals: Despite short-term bullish momentum, monthly technical indicators remain bearish or neutral, reflecting longer-term caution. The stock’s operating profit has declined at an annualised rate of -9.97% over five years, and recent financial results were flat, with operating profit to net sales ratio at a low 12.34%. Daily moving averages are mildly bearish, and the stock remains below its 52-week high of Rs.1,064.70, indicating resistance overhead. Volume declined towards week-end, signalling reduced trading interest.
Performance Context: Alembic Pharmaceuticals underperformed the Sensex over the week (-1.44% vs flat), but outperformed on several shorter-term horizons, including a 15.10% gain over the past month versus the Sensex’s 1.21%. The stock’s three-year return of 29.33% also surpasses the Sensex’s 16.84%, though longer-term returns over five and ten years lag the benchmark significantly.
Conclusion
The week for Alembic Pharmaceuticals Ltd. was characterised by mixed technical momentum and a pivotal upgrade in analyst rating. While the stock faced selling pressure to close the week lower, the technical upgrade to Hold and positive weekly indicators suggest a stabilising price trend after recent volatility. Investors should remain cautious given the conflicting monthly signals and flat financial performance, but the attractive valuation and institutional backing provide a foundation for potential consolidation or modest recovery. Monitoring key support near Rs.818 and resistance around Rs.854 will be essential in assessing the stock’s next directional move amid ongoing sector and market dynamics.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
